[关键词]
[摘要]
目的 探讨强骨生血口服液对雌性去卵巢大鼠骨质疏松的治疗作用及作用机制。方法 将18周龄雌性SD大鼠按体质量随机分为假手术、模型组、仙灵骨葆胶囊(0.54 g/kg)组和强骨生血口服液低、中、高剂量(2.7、5.4、10.8 mL/kg)组,除假手术外,其余各组进行双侧卵巢切除术制备骨质疏松模型。术后3 d开始给药,连续90 d。于给药第45、90天分别检测血钙、血清I型前胶原羧基末端肽(CTX-I)、骨钙、股骨羟脯氨酸水平,股骨腰椎骨密度(BMD)、断裂载荷、最大载荷值以及组织病理学检测。结果 与模型组比较,强骨生口服液低、中剂量可抑制去卵巢诱导的大鼠血钙、骨钙、BMD的降低,降低血清CTX-I水平,改善骨生物力学性能;强骨生口服液高剂量可显著抑制去卵巢诱导的大鼠血钙、骨钙、BMD的降低,降低血清CTX-I水平,改善骨生物力学性能。结论 强骨生血口服液对去卵巢诱导的大鼠骨质疏松具有延缓和治疗作用,其机制与减少骨钙丢失,降低CTX-I水平有关。
[Key word]
[Abstract]
Objective To study the effect of Qianggu Shengxue Oral Liquid (QSOL) on ovariectomy-induced osteoporosis in female rats. Methods 18-weeks old female SD rats were randomly divided into six groups:Sham, ovariectomized model group (OVX), three different doses of XLGB-treated groups after OVX (2.7, 5.4, and 10.0 mL/kg), and a positive drug group treated with xian-ling-gu-bao capsule (0.54 g/kg). In addition to the sham operation, the other groups were subjected to bilateral ovariectomy to establish osteoporosis model. Three days after the ovariectomized operation, rats were orally treated with drugs once per day for 90 continuous days. On the 45th day and the 90th day after given drugs, blood calcium, C-terminal telopeptides of type Icollagen (CTX-I) in serum, bone calcium, hydroxyproline, bone mineral density (BMD), femur bone, and the fourth lumbar vertebra (LV4) for the fracture load, maximum load and histopathologic examination were detected. Results Compared with the model group, the middle and low dose of QSOL can attenuate the decreases in blood calcium, BMD and bone density, decrease the level of serum CTX-I, and improve bone biomechanical property induced by ovariectomy in female rats; The high dose of QSOL can significantly attenuate these decreases in blood calcium, BMD and bone density, decrease the level of serum CTX-I, and improve bone biomechanical performance. Conclusion QSOL oral liquid can delay disease progress and treat the osteoporosis induced by ovariectomy, and the mechanism is related to the reduction in bone calcium loss and the level of CTX-I.
[中图分类号]
[基金项目]
湖湘青年创新人才基金(2014);新药药效与安全评价湖南省重点实验室开放性课题(201601)